SynthesisFrontiers in endocrinology2025
A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Targeting MicroRNA-21 in Chronic Kidney Disease: Lessons from the Lademirsen Story.Medical sciences (Basel, Switzerland) · 2026Review
- Review
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- Extracellular Vesicle-Derived MicroRNAs as Early Diagnostic Biomarkers of Diabetic Nephropathy and Cardiovascular Diseases in Type 2 Diabetes.International journal of molecular sciences · 2026Review
- Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases.Frontiers in molecular biosciences · 2026Review
- miRNA in the Progression of Diabetic Kidney Disease: New Insight.International journal of molecular sciences · 2025Review
- MiR-216a-5p protects against high glucose-induced HMC injury by targeting the HMGB1/RAGE signaling pathway.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to comprehensively assess the overall diagnostic value of circulating microRNAs (miRNAs or miRs) as biomarkers for the early diagnosis of diabetic kidney disease (DKD) through Meta-analysis, and to identify potential molecular biomarkers with higher diagnostic value for early DKD. Methods: The CNKI, Wanfang date, VIP, Pubmed, Embase, Web of Science, and Cochrane Library until January 2024 were searched. Relevant studies associated with the value of miRNAs in the diagnosis of early DKD were selected. Case numbers, sensitivity, and specificity were extracted from the included literature for both the observation and control groups. Results: Nine studies including 655 cases of early DKD patients and 664 cases as a control group were conducted. The comprehensive sensitivity was 0.76, comprehensive specificity was 0.74, combined positive likelihood ratio was 2.9 and the combined negative likelihood ratio was 0.33, diagnostic odds ratio (DOR) was 9. The summary receiver operating characteristic (SROC) curve was drawn and the area under the curve (AUC) was 0.79. Blood and urine source data were analyzed and showed that urine source miRNA had a higher sensitivity (0.82vs 0.68) and a higher DOR (10.5vs 8.2) than blood source miRNA. Conclusion: MiRNAs may serve as promising noninvasive biomarkers for the early diagnosis of DKD. The diagnostic value of miRNAs in urine samples may be higher than that in blood samples. The combined detection of some miRNAs or other clinical indicators can enhance the accuracy of early DKD diagnosis. Systematic Review Registration: https://osf.io, identifier DOI: 10.17605/OSF.IO/FC6DK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.